Mizuho Downgrades Atara Biotherapeutics to Neutral, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has downgraded Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Neutral and lowered the price target from $31 to $1.
November 09, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Atara Biotherapeutics has been downgraded from Buy to Neutral by Mizuho, with a significant price target reduction from $31 to $1.
The downgrade from Buy to Neutral indicates a less optimistic outlook for the company's stock. The drastic reduction in price target from $31 to $1 suggests that the analyst believes the stock is significantly overvalued. This could lead to a decrease in the stock's price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100